• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Trillsch, F.
    Mahner, S.
    Ataseven, B.
    Asher, R.
    Aryal, N.
    Dubot, C.
    Clamp, A.
    Penson, R. T.
    Oza, A.
    Amit, A.
    Huzarski, T.
    Casado, A.
    Scambia, G.
    Friedlander, M.
    Colombo, N.
    Fujiwara, K.
    Sonke, G. S.
    Denys, H.
    Lowe, E. S.
    Lee, C. K.
    Pujade-Lauraine, E.
    Show allShow less
    Affiliation
    Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. Electronic address: Fabian.Trillsch@med.uni-muenchen.de. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany; Ev. Kliniken Essen Mitte, Essen, Germany. University of Sydney, Camperdown, Sydney, Australia. Institut Curie, Hôpital René Huguenin, Saint Cloud and GINECO, France. The Christie NHS Foundation Trust, Manchester, UK. Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. Princess Margaret Cancer Centre, Toronto, Canada. Rambam Health Care Campus, affiliated with Rappaport Faculty of Medicine, Technion, Haifa, Israel. Pomeranian Medical University, Szczecin, Poland. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria (IdISSC) and CIBERONC, Madrid, Spain. Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica, Rome, Italy. University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, Australia. University of Milan-Bicocca and IEO, European Institute of Oncology IRCCS, Milan, Italy. Saitama Medical University International Medical Center, Saitama and Gynecologic Oncology Trial and Investigation Consortium (GOTIC), Japan. The Netherlands Cancer Institute, Amsterdam, the Netherlands. Ghent University Hospital, Ghent, Belgium. AstraZeneca, Gaithersburg, MD, USA. ARCAGY-GINECO Université Paris Descartes, AP-HP, Paris, France.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Background Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. Methods 295 patients from the SOLO2 trial randomly assigned to olaparib or placebo were categorized according to age-cutoff at 65 years. Efficacy, tolerability, and quality of life (QoL) of olaparib relative to placebo within in each age group was analyzed. Results Baseline characteristics were similar in patients ≥65 years (N = 62;21.0%) compared to patients <65 years (N = 233;78.9%). No significant difference in the magnitude of progression-free survival (PFS) benefit from olaparib for older patients (N = 40, hazard ratio [HR]≥65 0.43, 95%-confidence interval [CI] 0.24–0.81) as compared with younger patients (N = 155, HR<65 0.31 (95%-CI 0.22–0.43) was seen (interaction P = 0.33). The overall survival (OS)benefit seen in younger patients in the olaparib arm was not observed in older patients. Older and younger patients had comparable safety profiles and QoL scores although higher discontinuation rates for toxicity, and higher frequency of AML/MDS were noted in the older subset. TWiST analysis revealed clinically meaningful duration of good QoL on olaparib for both age groups (≥65: 13.5 vs <65: 18.4 months, P = 0.05). Conclusions Results of this large phase III cohort of BRCA1/2-mutated PSOC patients treated with olaparib underline impressive efficacy of olaparib maintenance irrespective of age. Although toxicity and tolerability did not raise significant concerns, some caution, close monitoring, and follow-up needs to be exercised for older patients given higher discontinuation rates, frequency of AML/MDS, and no clear effects on OS.
    Citation
    Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, et al. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecologic Oncology. Elsevier BV; 2022.
    Journal
    Gynecol Oncol
    URI
    http://hdl.handle.net/10541/625061
    DOI
    10.1016/j.ygyno.2022.01.024
    PubMed ID
    35115180
    Additional Links
    https://dx.doi.org/10.1016/j.ygyno.2022.01.024
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ygyno.2022.01.024
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.